Perimeter Medical Imaging AI's 'Claire' Becomes First FDA-approved AI-Enabled Imaging Device for Breast Cancer Surgery

Executive Summary

• Perimeter Medical Imaging AI received FDA Premarket Approval for Claire™, the first AI‑enabled intra‑operative breast cancer margin assessment device in the United States.
• The pivotal clinical trial showed 88.1% margin accuracy and a statistically significant reduction in residual cancer compared with standard care, indicating potential to lower repeat surgery rates (~20%).
• Company plans a nationwide commercial launch within weeks, positioning Claire as a scalable platform for ~300,000 annual U.S. breast‑conserving surgeries and future expansion into other oncology indications.

Key Details

• Regulatory Milestone: FDA PMA granted; device also received Breakthrough Device designation.
• Clinical Performance:
• Margin accuracy: 88.1%.
• Demonstrated statistically significant reduction in patients with residual cancer post‑surgery versus standard of care.
• Trial presented at ASBrS 2025, meeting “super‑superiority” criteria (lower bound CI > pre‑specified minimal clinically meaningful difference).
• Technology Highlights:
• Combines proprietary AI with patented wide‑field OCT imaging (10× higher resolution than X‑ray/ultrasound, 2 mm depth).
• Trained on >2 million breast tissue images; continuous learning from each procedure.
• Pre‑determined change control plan allows AI enhancements without additional FDA interaction.
• Market Opportunity:
• Targets ~300,000 annual U.S. breast‑conserving surgeries.
• Platform can be extended to other cancer surgeries, biopsy procedures, and pathology applications.
• Funding Support: Trial funded in part by a US$7.4 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
• Commercial Plan: Nationwide rollout slated for “the coming weeks,” enabling real‑time margin assessment to reduce repeat surgeries and associated patient anxiety/costs.
• Executive Comments:
• CEO Adrian Mendes emphasized the milestone’s impact on reducing re‑operations and improving patient outcomes.
• Chamath Palihapitiya highlighted the clinical and commercial potential, noting the device’s ability to provide peace of mind for surgeons and patients.

Notable Quotes

“Claire's FDA approval marks a major milestone in breast cancer care… we plan to begin a nationwide launch in the coming weeks so that surgeons can rapidly adopt the industry's first FDA‑approved real‑time AI‑powered imaging technology for breast cancer surgery.” – Adrian Mendes, CEO

“Claire delivers greater peace of mind… This is exactly the kind of AI‑driven innovation that can improve the standard of care by delivering measurable, real‑world medical impacts.” – Chamath Palihapitiya, Investor

Materiality Assessment: Material – Positive (first FDA‑approved AI device in its class; significant clinical benefit and commercial upside).